Audit a URL →

Sign in Sign up free

Loading…

Weekly · Sunday Morning

Five longevity claims.
Worth your time.
Every Sunday.

Last Sunday

Rapamycin extends mouse lifespan 9–14%
NAD+ precursors reverse aging in humans
Blue-light glasses improve sleep quality
Walking 10 min after meals blunts glucose
Verdict change — caffeine half-life downgraded

5 audits·1 verdict change·0 affiliate links·Every Sunday

Joining 1,247 readers — founders, MDs, and longevity-obsessed people who fact-check their own health decisions.

Browse

Decisions Claims Content Creators

Product

Audit a URL Sunday roundup API (soon)Pricing

About

FAQ Methodology Editorial Standards Corrections Press & brand RSS feed

Legal

Terms of Service Privacy Policy DMCA

Finally, something serious in this space.
Because we actually read the papers.

© 2026 Whalespan. Independent, evidence-graded longevity.

Do Longevity Drugs Have Additive Benefits? | Brian Kennedy, Ph.D. — Whalespan

Content›Video›Do Longevity Drugs Have Addi…

Do Longevity Drugs Have Additive Benefits? | Brian Kennedy, Ph.D.

Peter Attia9m · 2025-08-08

Claims Made

16

Claims Supported

10

Support Rate

63%

Support rate

10 of 16 claims supported

10 supported6 partial / not

Claims from this content

14

✓Well SupportedHigh VO2 max, muscle mass, and strength are superior predictors of lifespan compared to cholesterol, blood pressure, blood glucose, and smoking.✓Well SupportedMaintaining high lean muscle mass is likely more beneficial for health than being slightly leaner with lower muscle mass.✓Well SupportedIndividuals should be empowered to make their own health decisions, understanding the benefits and risks of interventions.✕Not SupportedTaking doses of GLP-1 agonists far greater than what the body naturally produces can lead to downstream consequences, including muscle wasting.Not Supported

More from Peter Attia

Peter Attia on Zone 2 Cardio

Peter Attia on Rapamycin (with Matt Kaeberlein)

Attia walks back the clinic protocol: too aggressive for healthy adults

Discussion

Native comments, Twitter mentions, and Reddit threads about this content — surfaced together so the conversation isn't fragmented across platforms.

M

Share your read of this content…

Posting publicly as you · linked to your social profiles

Sort by:

AV

A. Volkovreader

4h

Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.

NP

N. Park

2d

Would love a "what would change this verdict" RSS feed. Sign me up if it exists.

✕

Taking numerous health interventions simultaneously makes it impossible to determine their individual effectiveness or interactions.

◐Partially SupportedIf glucose homeostasis can be corrected through diet, sleep, and exercise, then GLP-1 agonists and SGLT2 inhibitors may not be targeting fundamental aging processes.

◐Partially SupportedLower hemoglobin A1C levels are associated with better all-cause mortality, even within the healthy range.

?Limited ResearchGLP-1 agonists and SGLT2 inhibitors may primarily benefit individuals with glucose irregularities, and their effect in perfectly optimized individuals is uncertain.

◐Partially SupportedExtreme weakness, low muscle mass, and poor fitness are more lethal than smoking, type 2 diabetes, or cancer.

◐Partially SupportedTest one or two interventions at a time and measure responses to understand individual effects.

◐Partially SupportedFor people unable to adhere to strict caloric restriction, pharmacological interventions like GLP-1 agonists, rapamycin, carbos, SGLT2 inhibitors, and metformin are potential alternatives to test for longevity benefits.

◐Partially SupportedCombining SGLT2 inhibitors and GLP-1 agonists may offer protection, with rapamycin potentially adding a different benefit.

?Limited ResearchThe potential for GLP-1 agonists and SGLT2 inhibitors to cause lean muscle mass loss is a concern, with varying opinions among doctors.

◐Partially SupportedExtending lifespan in mice with short-lived controls only indicates longevity normalization, not slowing of aging, which requires extension in long-lived controls.